Literature DB >> 33478471

Allergen fragrance molecules: a potential relief for COVID-19.

Aslı Deniz Aydın1, Faruk Altınel2, Hüseyin Erdoğmuş1, Çağdaş Devrim Son3.   

Abstract

BACKGROUND: The latest coronavirus SARS-CoV-2, discovered in China and rapidly spread Worldwide. COVID-19 affected millions of people and killed hundreds of thousands worldwide. There are many ongoing studies investigating drug(s) suitable for preventing and/or treating this pandemic; however, there are no specific drugs or vaccines available to treat or prevent SARS-CoV-2 as of today.
METHODS: Fifty-eight fragrance materials, which are classified as allergen fragrance molecules, were selected and used in this study. Docking simulations were carried out using four functional proteins; the Covid19 Main Protase (MPro), Receptor binding domain (RBD) of spike protein, Nucleocapsid, and host Bromodomain protein (BRD2), as target macromolecules. Three different software, AutoDock, AutoDock Vina (Vina), and Molegro Virtual Docker (MVD), running a total of four different docking protocol with optimized energy functions were used. Results were compared with the five molecules reported in the literature as potential drugs against COVID-19. Virtual screening was carried out using Vina, molecules satisfying our cut-off (- 6.5 kcal/mol) binding affinity was confirmed by MVD. Selected molecules were analyzed using the flexible docking protocol of Vina and AutoDock default settings.
RESULTS: Ten out of 58 allergen fragrance molecules were selected for further docking studies. MPro and BRD2 are potential targets for the tested allergen fragrance molecules, while RBD and Nucleocapsid showed weak binding energies. According to AutoDock results, three molecules, Benzyl Cinnamate, Dihydroambrettolide, and Galaxolide, had good binding affinities to BRD2. While Dihydroambrettolide and Galaxolide showed the potential to bind to MPro, Sclareol and Vertofix had the best calculated binding affinities to this target. When the flexible docking results analyzed, all the molecules tested had better calculated binding affinities as expected. Benzyl Benzoate and Benzyl Salicylate showed good binding affinities to BRD2. In the case of MPro, Sclareol had the lowest binding affinity among all the tested allergen fragrance molecules.
CONCLUSION: Allergen fragrance molecules are readily available, cost-efficient, and shown to be safe for human use. Results showed that several of these molecules had comparable binding affinities as the potential drug molecules reported in the literature to target proteins. Thus, these allergen molecules at correct doses could have significant health benefits.

Entities:  

Keywords:  Anti-viral fragrance molecules; COVID-19; Coronavirus; Docking; Fragrance allergen molecules; SARS-CoV-2

Year:  2021        PMID: 33478471      PMCID: PMC7819625          DOI: 10.1186/s12906-021-03214-4

Source DB:  PubMed          Journal:  BMC Complement Med Ther        ISSN: 2662-7671


  32 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.

Authors:  Zhenwei Wang; Xiaorong Chen; Yunfei Lu; Feifei Chen; Wei Zhang
Journal:  Biosci Trends       Date:  2020-02-09       Impact factor: 2.400

3.  Drug treatment options for the 2019-new coronavirus (2019-nCoV).

Authors:  Hongzhou Lu
Journal:  Biosci Trends       Date:  2020-01-28       Impact factor: 2.400

Review 4.  Application of Artificial Intelligence in COVID-19 drug repurposing.

Authors:  Sweta Mohanty; Md Harun Ai Rashid; Mayank Mridul; Chandana Mohanty; Swati Swayamsiddha
Journal:  Diabetes Metab Syndr       Date:  2020-07-03

5.  Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR.

Authors:  Jaegyun Lim; Seunghyun Jeon; Hyun Young Shin; Moon Jung Kim; Yu Min Seong; Wang Jun Lee; Kang Won Choe; Yu Min Kang; Baeckseung Lee; Sang Joon Park
Journal:  J Korean Med Sci       Date:  2020-02-17       Impact factor: 2.153

Review 6.  The SARS-CoV-2 main protease as drug target.

Authors:  Sven Ullrich; Christoph Nitsche
Journal:  Bioorg Med Chem Lett       Date:  2020-07-02       Impact factor: 2.823

7.  Structural basis of receptor recognition by SARS-CoV-2.

Authors:  Jian Shang; Gang Ye; Ke Shi; Yushun Wan; Chuming Luo; Hideki Aihara; Qibin Geng; Ashley Auerbach; Fang Li
Journal:  Nature       Date:  2020-03-30       Impact factor: 49.962

8.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.

Authors:  Chih-Cheng Lai; Tzu-Ping Shih; Wen-Chien Ko; Hung-Jen Tang; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2020-02-17       Impact factor: 5.283

9.  Going global - Travel and the 2019 novel coronavirus.

Authors:  Alfonso J Rodríguez-Morales; Kirsten MacGregor; Sanch Kanagarajah; Dipti Patel; Patricia Schlagenhauf
Journal:  Travel Med Infect Dis       Date:  2020-02-08       Impact factor: 6.211

10.  PubChem in 2021: new data content and improved web interfaces.

Authors:  Sunghwan Kim; Jie Chen; Tiejun Cheng; Asta Gindulyte; Jia He; Siqian He; Qingliang Li; Benjamin A Shoemaker; Paul A Thiessen; Bo Yu; Leonid Zaslavsky; Jian Zhang; Evan E Bolton
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

View more
  2 in total

1.  Essential Oil Disinfectant Efficacy Against SARS-CoV-2 Microbial Surrogates.

Authors:  Emily S Bailey; Marina Curcic; Jnev Biros; Hüseyin Erdogmuş; Nurcan Bac; Albert Sacco
Journal:  Front Public Health       Date:  2021-12-14

Review 2.  The bioactivities of sclareol: A mini review.

Authors:  Jianbo Zhou; Xiaofang Xie; Hailin Tang; Cheng Peng; Fu Peng
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.